0001058290-25-000267
SEC filingNotes reveal strong cash generation, with $1.8B cash, $592M debt, and $6.1B RPO; segment margins improved.
Cash and cash equivalents stood at $1,796M as of June 30, 2025, down from $2,231M at year-end 2024, primarily due to share repurchases and dividend payments. Total investments (short-term and long-term) were $122M. Total debt decreased to $592M, with the revolver fully repaid ($300M) and term loan reduced by $21M. Shareholders' equity rose to $15,288M from $14,408M, driven by net income and OCI gains. Deferred revenue (current and noncurrent) totaled $474M.
Remaining performance obligations (RPO) were $6,082M as of June 30, 2025, with approximately 35% expected within one year, 55% within two years, and 90% within five years. No material purchase commitments for inventory or capacity were disclosed in the Notes. Legal contingencies include ongoing tax disputes with the Indian tax department (ITD) and class action litigation; specific reserves have not been recorded for uncertain tax positions or the discrimination lawsuit.
Share repurchases totaled $582M (7M shares) in the first half of 2025. Dividends increased to $0.31 per quarter, resulting in $308M paid. Capital expenditures were $144M, representing 1.39% of revenue. No new debt was issued; net debt reduction was $316M. The company maintains a $650M term loan and $1,850M revolving credit facility (undrawn as of June 30).
Segment operating profit for the six months: Health Sciences $609M (19.5% margin), Financial Services $508M (16.9%), Products & Resources $392M (15.2%), Communications, Media & Technology $207M (12.6%). Revenue growth was strongest in P&R (+14.4% YoY) and HS (+8.5%). North America contributed 75% of total revenue, Europe 19%, Rest of World 6%. Segment operating profit improvements were driven by cost allocations and revenue mix.
Net income of $1,308M exceeded operating cash flow of $798M, indicating significant working capital outflows. Key drivers: trade receivables increased $320M, other liabilities decreased $388M, and deferred revenues fell $10M. Capex of $144M (18% of CFO) was moderate. Capital returns (share repurchases $577M + dividends $308M) totaled $885M, surpassing CFO, requiring cash draws. Investing activities included $70M proceeds from sale of property, partly offsetting capex. Financing activities included $300M repayment of revolving credit facility. One-time gain of $62M on sale of property and equipment boosted net income but was non-cash.